CN116077586A - Dendrobium officinale and ginseng immunity enhancing pharmaceutical composition and preparation method and application thereof - Google Patents
Dendrobium officinale and ginseng immunity enhancing pharmaceutical composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN116077586A CN116077586A CN202211370461.9A CN202211370461A CN116077586A CN 116077586 A CN116077586 A CN 116077586A CN 202211370461 A CN202211370461 A CN 202211370461A CN 116077586 A CN116077586 A CN 116077586A
- Authority
- CN
- China
- Prior art keywords
- parts
- water
- medicines
- dendrobium
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 22
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 241001076416 Dendrobium tosaense Species 0.000 title claims abstract description 21
- 241000208340 Araliaceae Species 0.000 title claims abstract 9
- 230000036039 immunity Effects 0.000 title claims description 25
- 230000002708 enhancing effect Effects 0.000 title claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 144
- 239000003814 drug Substances 0.000 claims abstract description 107
- 229940079593 drug Drugs 0.000 claims abstract description 89
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 76
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 76
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 76
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 76
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 76
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 76
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 76
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 76
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 76
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 76
- 241000026010 Dendrobium candidum Species 0.000 claims abstract description 76
- 239000000706 filtrate Substances 0.000 claims abstract description 72
- 235000006533 astragalus Nutrition 0.000 claims abstract description 65
- 238000002791 soaking Methods 0.000 claims abstract description 56
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 43
- 238000001914 filtration Methods 0.000 claims abstract description 43
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 36
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 36
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 36
- 238000003756 stirring Methods 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 238000001816 cooling Methods 0.000 claims abstract description 23
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 208000031971 Yin Deficiency Diseases 0.000 claims abstract description 9
- 241001092040 Crataegus Species 0.000 claims description 75
- 235000013399 edible fruits Nutrition 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 38
- 239000000284 extract Substances 0.000 claims description 30
- 241001061264 Astragalus Species 0.000 claims description 23
- 210000004233 talus Anatomy 0.000 claims description 23
- 238000011068 loading method Methods 0.000 claims description 20
- 240000004638 Dendrobium nobile Species 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 235000010241 potassium sorbate Nutrition 0.000 claims description 4
- 239000004302 potassium sorbate Substances 0.000 claims description 4
- 229940069338 potassium sorbate Drugs 0.000 claims description 4
- 239000008119 colloidal silica Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 240000002948 Ophiopogon intermedius Species 0.000 claims 7
- 235000021551 crystal sugar Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 35
- 230000001737 promoting effect Effects 0.000 abstract description 25
- 210000002784 stomach Anatomy 0.000 abstract description 13
- 241001523681 Dendrobium Species 0.000 abstract description 11
- 238000004806 packaging method and process Methods 0.000 abstract description 8
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 206010039424 Salivary hypersecretion Diseases 0.000 abstract description 3
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 208000026451 salivation Diseases 0.000 abstract description 3
- 235000013355 food flavoring agent Nutrition 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 70
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 34
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 34
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 34
- 230000008569 process Effects 0.000 description 34
- 239000006072 paste Substances 0.000 description 33
- 229920001282 polysaccharide Polymers 0.000 description 28
- 239000005017 polysaccharide Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000011160 research Methods 0.000 description 27
- 150000004676 glycans Chemical class 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 238000000605 extraction Methods 0.000 description 24
- 229940107666 astragalus root Drugs 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 241000405414 Rehmannia Species 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 19
- 239000000523 sample Substances 0.000 description 17
- 235000000346 sugar Nutrition 0.000 description 16
- 229930182490 saponin Natural products 0.000 description 15
- 235000017709 saponins Nutrition 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 240000005373 Panax quinquefolius Species 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 238000011835 investigation Methods 0.000 description 10
- 230000003647 oxidation Effects 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- -1 saponin compound Chemical class 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 229930195210 Ophiopogon Natural products 0.000 description 9
- 229930003944 flavone Natural products 0.000 description 9
- 235000011949 flavones Nutrition 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 238000003809 water extraction Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 150000002212 flavone derivatives Chemical class 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- BQPYEFAVIPEQIK-CKXSKKTQSA-N Spinasaponin A Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@@H]4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1 BQPYEFAVIPEQIK-CKXSKKTQSA-N 0.000 description 6
- KNZSXKKCTOYLSV-VHHWNNOGSA-N ac1l462r Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1CC2=CCC3C4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CCC3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O KNZSXKKCTOYLSV-VHHWNNOGSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000011020 pilot scale process Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- KNZSXKKCTOYLSV-UHFFFAOYSA-N trigofoenoside A Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O KNZSXKKCTOYLSV-UHFFFAOYSA-N 0.000 description 6
- 239000009636 Huang Qi Substances 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000022 bacteriostatic agent Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 150000001629 stilbenes Chemical class 0.000 description 3
- 235000021286 stilbenes Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000018927 edible plant Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229930182489 iridoid glycoside Natural products 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000013386 optimize process Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Chemical class 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 150000005856 steroid saponins Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 150000003521 tetracyclic triterpenoids Chemical class 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical class [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a dendrobium candidum and ginseng immunity-enhancing pharmaceutical composition, and a preparation method and application thereof, wherein the dendrobium candidum and ginseng immunity-enhancing pharmaceutical composition comprises the following raw materials: dendrobium officinale, astragalus membranaceus, radix pseudostellariae, radix rehmanniae, charred hawthorn, radix ophiopogonis and sodium benzoate, and the preparation method comprises the following steps: soaking six Chinese medicinal decoction pieces such as herba Dendrobii in filter bag for 2 hr, decocting for 3 times, adding 8 times of water for the first time, adding 6 times of water for 2 nd and 3 times, decocting for 30min, filtering, mixing decoctions, concentrating the filtrate to relative density of 1.10-1.13 at 50deg.C, adding sodium benzoate, stirring, dissolving, mixing, cooling, and packaging. The obtained pharmaceutical composition has effects of nourishing yin, clearing heat, invigorating qi, promoting salivation, and invigorating stomach. The preparation method is simple and convenient, is convenient for production control, has good stability and high safety, and can be used for standardized and large-scale production; the prepared product has good taste, is free from adding any flavoring agent, and is very suitable for children to take. Not only enriches the clinical medicines for treating children with lung-spleen yin deficiency syndrome, but also has important significance for promoting dendrobium to become the Guizhou big health industry.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a dendrobium nobile ginseng immunity-enhancing pharmaceutical composition, and a preparation method and application thereof.
Background
The invention aims to take the traditional rare traditional Chinese medicine "dendrobium" as a tongs and carry out the research and development of hospital preparations on the empirical prescription "Dendrobium ginseng immunity enhancing mixture (prescription: dendrobium officinale, astragalus, dwarf lilyturf tuber, radix pseudostellariae, dried rehmannia root and scorched hawthorn fruit)" which is the experience inheriter Chen Zhu of the national old traditional Chinese medicine expert academic experience with definite curative effect.
Dendrobium officinale is a dry stem of Dendrobium officinale Dendrobium officinale Kimura et Migo belonging to Orchidaceae. Harvesting for 11 months to 3 months next year, removing impurities, cutting off part of fibrous roots, twisting into spiral or spring shape while heating, and oven drying; or cutting into sections, drying or low-temperature drying, the former is known as "Dendrobium candidum" (Dendrobium otophyllum); the latter is known as "Dendrobium officinale". Sweet and slightly cold. Enter stomach and kidney meridians. Has effects of benefiting stomach, promoting salivation, nourishing yin, and clearing heat. Can be used for treating fever, fluid consumption, dry mouth, polydipsia, stomach yin deficiency, anorexia, retching, deficiency heat after illness, yin deficiency, fire hyperactivity, bone steaming, dim eyesight, and flaccidity of tendons and bones. Modern scientific research proves that the main active ingredients contained in the dendrobium candidum are dendrobium polysaccharide, dendrobine, astragalus, derivatives thereof, trace elements and the like [1] The chemical components of the dendrobium candidum are determined at present: polysaccharides, alkaloids, stilbenes, phenols, lignin, and the like, which have a variety of biological activities: regulating immunity, resisting oxidation, resisting tumor, reducing blood sugar, and resisting bacteria. [2] The dendrobium polysaccharide has close relation with the pharmacological activity. The polysaccharide content is the main basis for judging the quality of the dendrobium candidum. The dendrobium candidum polysaccharide has an antibacterial effect on staphylococcus aureus, escherichia coli and pneumococcus, and the result shows that the dendrobium candidum polysaccharide has an obvious antibacterial effect. [3] The fresh juice of Dendrobium officinale has analgesic and antiinflammatory effects. [4]
The radix astragali is dried root of Mongolian radix astragali Astragalus membranaceus (Fisch.) bge.var. Mongholicus (bge.) Hsiao or Astragalus membranaceus Astragalus membranaceus (Fisch.) bge. Collected in spring and autumn, removed fibrous root and root head, and dried in the sun. Sweet and slightly warm. Enter lung and spleen meridians. Tonifying qi and yang, strengthening exterior and arresting sweating, inducing diuresis and relieving edema, promoting fluid production and nourishing blood, promoting the circulation of qi and relieving arthralgia, expelling toxin and pus, healing sore and promoting tissue regeneration. Can be used for treating qi deficiency debilitation, loose stool, sinking of middle-jiao, chronic diarrhea rectocele, hematochezia metrorrhagia, spontaneous perspiration due to exterior deficiency, qi deficiency edema, internal heat diabetes, blood deficiency sallow complexion, hemiplegia, arthralgia, numbness, carbuncle, ulcer, and chronic ulcer Is not converged. Researchers have extracted and separated components such as saponins, polysaccharides, flavones, sterols, amino acids and volatile oils from astragalus. Wherein the components such as saponins, polysaccharides and flavonoids have remarkable chemical activity. The saponin compound is one of important active ingredients in astragalus mongholicus, and most of the saponin compounds are tetracyclic triterpenoid saponin compounds. More than 40 kinds of saponin compounds have been separated from Mongolian radix astragali, membranous milkvetch root and its congeneric plants, mainly including astragalus saponins I-VIII, iso-astragalus saponins I-IV, acetyl astragalus saponins, soybean saponins, etc [5] . Astragaloside IV (AS-IV) is a main component of astragalus root with heart strengthening effect, and has wide biological activities of protecting heart, resisting inflammation, resisting oxidation, resisting apoptosis, resisting virus, etc. [6] Astragalus Polysaccharides (APS) are the active ingredients with the highest activity in astragalus medicinal materials, and are also the hot content of modern medical research. APS are mainly composed of glucans, including water-soluble and water-insoluble glucans, and heteropolysaccharides, mostly water-soluble acidic heteropolysaccharides. APS participates in regulating organism immunity, and has anti-tumor, anti-infection activity, and cardiovascular protection effects [7] . A great deal of experimental researches show that the APS and the astragaloside have obvious immunoregulation effect [8] 。
Radix Pseudostellariae is dried root tuber of radix Pseudostellariae Pseudostellaria heterophylla (Miq.) Pax ex Pax et Hoffm of Caryophyllaceae. Most of the stems and leaves in summer withered are picked up, cleaned, removed, put into boiling water and dried in the sun or directly dried in the sun. Sweet and slightly bitter in flavor, neutral in nature. Enter spleen and lung meridians. Replenishing qi to invigorate the spleen, promoting fluid production and moistening the lung. Can be used for treating spleen deficiency, tiredness, inappetence, asthenia after illness, deficiency of qi and yin, spontaneous perspiration, thirst, and dry cough due to lung dryness. The radix pseudostellariae contains a plurality of active ingredients such as amino acid, polysaccharide, glycoside, phospholipid, cyclic peptide, volatile oil and the like, and the radix pseudostellariae has a plurality of biological activities such as enhancing organism, promoting immunity, SOD-like effect, relieving cough, resisting bacteria, resisting viruses and the like when reflecting the active ingredients. [9] The volatile oil content in the radix pseudostellariae is high, and researchers detect 78 volatile monomer components from the radix pseudostellariae volatile oil by using a GC-MS technology. The cyclopeptides are characteristic components of radix pseudostellariae, and researchers have separated 16 cyclopeptides from radix pseudostellariaeThe content of saponins in radix Pseudostellariae is low. Researchers separate and obtain various amino acids from radix pseudostellariae, wherein arginine content is highest, and contents of glutamic acid, alanine, aspartic acid and the like are also higher. [10]
Radix rehmanniae is fresh or dried root tuber of rehmannia Rehmannia glutinosa Libosch of Scrophulariaceae. Digging in autumn, removing head, fibrous root and silt, and fresh; or baking rehmanniae radix slowly until it is about eight times dry. The former is known as "fresh rehmannia root", and the latter is known as "Sheng Di Huang". The radix rehmanniae is sweet and cold. It enters heart, liver and kidney meridians. Clear heat and cool blood, nourish yin and promote the production of body fluid. Can be used for treating heat entering nutrient blood, toxic heat, speckle, hematemesis, epistaxis, yin injury due to heat disease, dark red tongue, polydipsia, constipation due to body fluid deficiency, yin deficiency, fever, bone steaming, internal heat, and diabetes. The main chemical components in the rehmannia root are saccharides, iridoid glycoside, amino acid and the like, which are also main active components. 8 sugars have been isolated and identified from rehmannia: stachyose, raffinose, glucose, sucrose, fructose, mannyltriase, verbascose and galactose. The rehmannia root has the highest polysaccharide component content and better water solubility, wherein the content of reducing sugar is 140.3-287.3mg.g -1 The method comprises the steps of carrying out a first treatment on the surface of the The polysaccharide content is 31.3-50.5 mg.g -1 。 [11] Rehmannia has the pharmacological activities of resisting oxidation, resisting aging, exciting immunity, reducing blood sugar, resisting cancer, resisting cerebral ischemia, protecting nerve center, promoting hematopoiesis and the like. The rehmannia polysaccharide has many pharmacological effects of resisting tumor, enhancing immunity, promoting hematopoiesis, reducing blood sugar, resisting oxidation, resisting anxiety, inducing BMSCs to differentiate into neuron-like cells, and is one of the main active ingredients of rehmannia. [12] The pharmacological experiment of the rehmannia glycoside D, A shows that the rehmannia glycoside D, A has the effects of nourishing yin, enriching blood and reducing blood sugar, and the research shows that the rehmannia glycoside D, A has good water solubility and strong thermal stability. [13]
The radix Ophiopogonis is dried root tuber of radix Ophiopogonis Ophiopogon japonicus (L.f) Ker-Gawl of Liliaceae. Collected in summer, washed, repeatedly exposed to the sun, piled up until the roots are dried, removed and dried. Sweet, slightly bitter and slightly cold. It enters heart, lung and stomach meridians. Nourishing yin, promoting salivation, moistening lung, and clearing away heart-fire. Can be used for treating cough due to yin deficiency, cough due to fatigue, sore throat, fluid consumption, thirst, internal heat, diabetes, vexation, insomnia, constipation due to intestinal dryness. Steroid saponin, highIsoflavone and ophiopogon polysaccharide are main active components of ophiopogon [14] . Radix Ophiopogonis flavone has physiological effects of resisting myocardial ischemia, resisting thrombosis, resisting oxidation, enhancing immunity, and resisting aging [15] Polysaccharide compounds in ophiopogon root have wide and effective functions, and monosaccharide composition mainly comprises fructose and glucose. The ophiopogon polysaccharide has the effects of reducing blood sugar, regulating immunity, relieving asthma, resisting allergy, resisting anoxia, resisting tumor, resisting myocardial ischemia and treating gastrointestinal tract. [16]
The fructus crataegi is dried mature fruit of Crataegus pinnatifida Crataegus pinnatifida Bge. Var. Major N.E. Br. or Crataegus pinnatifida Crat aegus pinnatifida Bge. Harvesting in autumn, slicing, and drying. Acid, sweet, slightly warm. It enters spleen, stomach and liver meridians. Promoting digestion, invigorating stomach, promoting qi circulation, removing blood stasis, eliminating turbid pathogen, and reducing blood lipid. Can be used for treating food stagnation, gastric distention, diarrhea, abdominal pain, blood stasis amenorrhea, puerperal blood stasis, especially abdominal pain, chest pain, hernia pain, and hyperlipidemia. The food-digesting and stagnation-removing effects of the charred fructus crataegi are enhanced. It can be used for treating food stagnation, diarrhea, and dysentery. Hawthorn is a medicinal and edible plant and contains various chemical components such as flavonoid, flavane, polymers thereof, triterpenes, organic acids and the like. The fructus crataegi total flavone has blood pressure lowering effect. [17] Flavone in fructus crataegi is the main component for reducing blood lipid. [18] The fructus crataegi decoction has effect in promoting cellular immunity of mice. Hawthorn flavone is a recognized class of compounds with the highest antioxidant potential. [19]
The invention carries out systematic pharmaceutical research on the dendrobium officinale and ginseng immunity enhancing mixture. Herba Dendrobii, sweet and slightly cold in the recipe, is a monarch drug, has the effects of nourishing yin, clearing heat, promoting fluid production and benefiting stomach, and is called as "nourishing yin, tonifying and precious product" in Ben Cao gang mu Mi Yi ". The radix pseudostellariae is sweet and flat and slightly bitter, is ministerial, can tonify qi of lung and spleen, promote fluid production and moisten lung, is a tonic for clearing and tonifying in qi-tonifying herbs, has mild action, and is suitable for the syndrome of deficiency of qi and yin of children. Astragalus root is also a ministerial drug, sweet and slightly warm, and enters lung and spleen meridians, so that the plum is called as "long of tonic" and astragalus root can tonify qi of the whole body, has the effects of invigorating yang, consolidating exterior and arresting sweating, expelling pus and promoting granulation, inducing diuresis and relieving edema, and has remarkable curative effects on infantile anemia, deficiency and hyperhidrosis, deficiency of both qi and blood, deficiency of yin and the like. The adjuvant drug ophiopogon root is sweet, slightly bitter and slightly cold, and the "Ben Cao Xin Zao" is called as "purging the internal heat of the lung, clearing heat evil in the stomach, removing deficiency heat, relieving lung dryness and relieving cough", and can strengthen the effects of nourishing yin, moistening lung, tonifying stomach and promoting fluid production ". The radix rehmanniae is sweet and cold, but has no greasy taste of prepared rehmannia root, can clear heat, nourish yin and promote the production of body fluid, and is suitable for the symptoms of incomplete waste heat and insufficient body fluid of children; the scorched hawthorn fruit is sweet and sour, slightly warm and unhealthy, has the functions of promoting digestion and invigorating stomach, and is good for promoting digestion and stagnation, and because most yin-nourishing medicines are sweet, cold and sticky, the scorched hawthorn fruit can pass qi and blood, so that the whole prescription is supplemented without stagnation and combined with dynamic and static. In conclusion, the whole formula has the effects of nourishing yin, clearing heat, tonifying qi, promoting the production of body fluid and tonifying stomach. After the invention is developed into the mixture, the drug effect substances of the traditional decoction are reserved, the stability of the product is improved by colleagues, the dosage is reduced, and the invention is more convenient for patients to carry. The clinical medicine for treating the children lung-spleen yin deficiency syndrome is enriched.
Disclosure of Invention
The invention aims to provide a dendrobium nobile ginseng immunity-enhancing pharmaceutical composition.
The invention also aims to provide a preparation method of the dendrobium candidum immunity-enhancing pharmaceutical composition.
The invention also aims to provide an application of the dendrobium candidum and ginseng immunity-enhancing pharmaceutical composition in preparing medicines for treating or/and preventing children's spleen-lung yin deficiency.
The invention is realized by the following scheme:
a pharmaceutical composition for enhancing immunity of dendrobium nobile lindl and ginseng comprises the following medicines in parts by weight: 152-168 parts of dendrobium candidum, 255-279 parts of astragalus membranaceus, 125-141 parts of radix pseudostellariae, 125-141 parts of radix rehmanniae, 125-141 parts of scorched hawthorn fruit and 125-141 parts of dwarf lilyturf tuber.
Further, the composition disclosed by the invention comprises the following medicines in parts by weight: 154-166 parts of dendrobium candidum, 258-276 parts of astragalus membranaceus, 127-139 parts of radix pseudostellariae, 127-139 parts of radix rehmanniae, 127-139 parts of scorched hawthorn fruit and 127-139 parts of dwarf lilyturf tuber.
Further, the composition disclosed by the invention comprises the following medicines in parts by weight: 156-164 parts of dendrobium candidum, 261-273 parts of astragalus membranaceus, 129-137 parts of radix pseudostellariae, 129-137 parts of radix rehmanniae, 129-137 parts of scorched hawthorn fruit and 129-137 parts of dwarf lilyturf tuber.
Further, the composition disclosed by the invention comprises the following medicines in parts by weight: 158-162 parts of dendrobium candidum, 264-270 parts of astragalus membranaceus, 131-135 parts of radix pseudostellariae, 131-135 parts of radix rehmanniae, 131-135 parts of scorched hawthorn fruit and 131-135 parts of dwarf lilyturf tuber.
Further, the composition of the invention comprises the following medicaments in part by weight: 160 parts of dendrobium candidum, 267 parts of astragalus membranaceus, 133 parts of radix pseudostellariae, 133 parts of radix rehmanniae, 133 parts of scorched hawthorn fruit and 133 parts of dwarf lilyturf tuber.
A preparation method of a dendrobium candidum and ginseng immunity-enhancing pharmaceutical composition comprises the following steps: loading six medicines of dendrobium officinale, astragalus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber in a prescription amount into a filter bag, soaking in water for 0.5-6h, decocting for 3 times, adding water which is 6-10 times of the total weight of the medicines in the first decoction, adding water which is 4-8 times of the total weight of the medicines in the second and third times, decocting for 0.5-1.0h each time, filtering, merging the decoctions, concentrating the filtrate to an extract with relative density of 1.05-1.18 at 50 ℃, adding sodium benzoate with the total amount of 0.1-0.3%, stirring, dissolving, cooling and split charging, or adding the collected filtrate into pharmaceutically acceptable auxiliary materials to prepare a pharmaceutically acceptable dosage form.
Further, the preparation method of the invention comprises the following steps: filling six medicines of dendrobium officinale, astragalus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking in water for 2 hours, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5 hour each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, cooling, split charging, or adding the collected filtrate into pharmaceutically acceptable auxiliary materials to prepare a pharmaceutically acceptable dosage form.
The acceptable auxiliary materials are one or more of sodium benzoate, sucrose, maltose, rock sugar, refined honey, dextrin, colloidal silicon dioxide and starch.
The acceptable dosage forms of the invention are mixture, paste, granule, syrup, pill and tablet.
The invention discloses application of a dendrobium candidum and ginseng immunity-enhancing pharmaceutical composition in preparing medicines for treating or/and preventing lung-spleen yin deficiency syndrome of children.
The invention has the following beneficial effects:
1. the invention obtains the water absorption rate test of decoction pieces: the water absorption rate of the decoction pieces is highest, namely about 1.7 times, for convenient operation, the water absorption rate is calculated to be 2 times, namely, the water absorption rate of the decoction pieces is 2 times of the weight of the decoction pieces, and the water absorption rate of the decoction pieces is basically satisfied, so that the water with the weight of 2 times of the weight of the decoction pieces is added in the first extraction, and a foundation is laid for the subsequent water extraction process investigation.
2. According to the invention, through investigation of the soaking time, the yield of total solids and the astragaloside IV content in the extracting solution are taken as investigation indexes, and the proper soaking time is optimized, so that the method is characterized in that the method comprises the following steps of: the paste yield is relatively high in 2h and 6h, and is 28.6 percent and 31.7 percent respectively, and the paste yield is relatively high in 6h, so that the soaking time is 2h from the aspects of time cost and possibility of microorganism breeding due to overlong soaking time; the content of astragaloside IV is measured, and compared with the method of soaking for 6 hours, the content of astragaloside IV in a sample prepared by soaking for 2 hours and then decocting is slightly higher, and the content reaches 1.19mg, so that the soaking time is preferably 2 hours finally.
3. The invention carries out screening experiments on the decocting process conditions, adopts orthogonal experiments and analysis of variance, and obtains: the factors of the times of decoction are obviously different, and the excessive water addition can cause overlong subsequent concentration time, so the decoction is selected to be performed for 3 times, 30 minutes each time, and the water addition multiple is 6 times as the optimal extraction process, A 3 B 1 C 1 The method comprises the steps of carrying out a first treatment on the surface of the By combining the research results of the water absorption and the soaking time, the best finally determined decocting process is adding 8 times of water for soaking for 2 hours, decocting for 30 minutes, adding 6 times of water for the 2 nd time and the 3 rd time, and decocting for 30 minutes.
4. The invention carries out research and experiment on the concentration process to obtain: when the extract is concentrated to about the relative density of 1.10-1.13 (50 ℃), the pH and the product properties meet the relevant regulations of medicines.
5. According to 1121 antibacterial effectiveness inspection method of Chinese pharmacopoeia 2020 edition, the invention carries out investigation on the antibacterial agents with various prescription amounts to obtain the antibacterial agents with the following formula amounts: in the concentration range of 0.15% to 0.30%, both the potassium sorbate and the sodium benzoate can meet the requirements, but the concentration of the sodium benzoate for achieving better antibacterial effect is slightly lower, so that 0.2% of sodium benzoate is selected as the antibacterial agent of the product.
6. The method of the invention carries out comprehensive investigation on production process indexes through pilot scale research, carries out quality assessment on finished products, carries out relevant inspection on the relative density (20 ℃) of the finished products, the pH value, the astragaloside IV content and the loading quantity of the finished products, and obtains the product: the relative density of the product is between 1.12 and 1.14, the pH value is between 4.62 and 4.58, the astragaloside IV content is between 0.13 and 0.155, the loading is more than 150mL, the total number of mold and saccharomycetes is lower than 10cfu/mL, the escherichia coli is not detected, various indexes of the product meet the requirements, and the process conditions are stable and controllable, so that the optimized process can be used for the mass production of the product.
7. After the decoction is developed into the mixture, the medicinal effect substances of the traditional decoction are maintained, the stability of the product is improved, the dosage is reduced, and the decoction is more convenient for patients to carry. The prepared product has good taste, is free from adding any flavoring agent, and is very suitable for children to take.
Detailed Description
Specific technical effects of the present application will be described in detail below by way of examples so that those skilled in the art can better understand the spirit of the present application. It should be noted that the described embodiments are only some embodiments of the present application and not all embodiments. All other embodiments, which can be made by those skilled in the art without the inventive effort, are intended to be within the scope of the present application.
Example 1
The formula comprises the following components: 160g of dendrobium candidum, 267g of astragalus membranaceus, 133g of radix pseudostellariae, 133g of radix rehmanniae, 133g of scorched hawthorn fruit and 133g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5h each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 2
The formula comprises the following components: 168g of dendrobium candidum, 279g of astragalus membranaceus, 141g of radix pseudostellariae, 141g of radix rehmanniae, 141g of scorched hawthorn fruit and 141g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 6 hours, decocting for 3 times, adding 10 times of water for the total weight of the medicines in the first decoction, adding 8 times of water for the second and third times, decocting for 1.0 hour each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.13-1.18 at 50 ℃, adding sodium benzoate accounting for 0.3% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 3
The formula comprises the following components: 152g of dendrobium candidum, 255g of astragalus membranaceus, 125g of radix pseudostellariae, 125g of radix rehmanniae, 125g of scorched hawthorn fruit and 125g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking in water for 0.5h, decocting for 3 times, adding water which is 6 times of the total weight of the medicines in the first decoction, adding water which is 4 times of the total weight of the medicines in the second and third times, decocting for 0.5h each time, filtering, combining the filtrates obtained from the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.05-1.10 at 50 ℃, adding sodium benzoate accounting for 0.1% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 4
The formula comprises the following components: 160g of dendrobium candidum, 267g of astragalus membranaceus, 133g of radix pseudostellariae, 133g of radix rehmanniae, 133g of scorched hawthorn fruit and 133g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5h, filtering, combining the filtrates obtained in the 3 times of decoction, concentrating the filtrate to an extract with the relative density of 1.27-1.34 (50 ℃), adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the extract.
Example 5
The formula comprises the following components: 160g of dendrobium candidum, 267g of astragalus membranaceus, 133g of radix pseudostellariae, 133g of radix rehmanniae, 133g of scorched hawthorn fruit and 133g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six drugs of dendrobium officinale, astragalus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water for the total weight of the drugs in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 600g of sucrose, stirring, continuously concentrating to the relative density of 1.30-1.35 (80 ℃), preparing 1000g, and sub-packaging to obtain the soft extract.
Example 6
The formula comprises the following components: 160g of dendrobium candidum, 267g of astragalus membranaceus, 133g of radix pseudostellariae, 133g of radix rehmanniae, 133g of scorched hawthorn fruit and 133g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus membranaceus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, adding water for 2.5h, decocting for 3 times, adding water 10 times of the total weight of the medicines in the first decoction, adding water 8 times of the total weight of the medicines in the second and third times, decocting for 1h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 500g of maltose, stirring, continuously concentrating to the relative density of 1.30-1.35 (80 ℃), preparing 1000g, and subpackaging to obtain the decocted paste.
Example 7
The formula comprises the following components: 168g of dendrobium candidum, 276g of astragalus mongholicus, 131g of radix pseudostellariae, 131g of radix rehmanniae, 131g of scorched hawthorn fruit and 131g of radix ophiopogonis.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus membranaceus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, adding water for 2.5h, decocting for 3 times, adding water 10 times of the total weight of the medicines in the first decoction, adding water 8 times of the total weight of the medicines in the second and third times, decocting for 1h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 600g of maltose, stirring and continuing concentrating to the relative density of 1.30-1.35 (80 ℃), preparing 1000g, and subpackaging to obtain the decocted paste.
Example 8
The formula comprises the following components: 152g of dendrobium candidum, 255g of astragalus, 129g of radix pseudostellariae, 129g of radix rehmanniae, 129g of scorched hawthorn fruit and 129g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus membranaceus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, adding water for 2.5h, decocting for 3 times, adding water 10 times of the total weight of the medicines in the first decoction, adding water 8 times of the total weight of the medicines in the second and third times, decocting for 1h, filtering, combining the filtrates obtained in the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 700g of rock sugar, stirring, continuously concentrating to the relative density of 1.30-1.35 (80 ℃), preparing 1000g, and subpackaging to obtain the soft extract.
Example 9
The formula comprises the following components: 164g of dendrobium candidum, 270g of astragalus, 127g of radix pseudostellariae, 127g of radix rehmanniae, 127g of charred hawthorn and 127g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus membranaceus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, adding water for 2.5h, decocting for 3 times, adding water 10 times of the total weight of the medicines in the first decoction, adding water 8 times of the total weight of the medicines in the second and third times, decocting for 1h, filtering, combining the filtrates obtained in the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 500g of refined honey, stirring, continuously concentrating to the relative density of 1.30-1.35 (80 ℃), preparing 1000g, and subpackaging to obtain the decocted paste.
Example 10
The formula comprises the following components: 160g of dendrobium candidum, 267g of astragalus membranaceus, 133g of radix pseudostellariae, 133g of radix rehmanniae, 133g of scorched hawthorn fruit and 133g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water of the total weight of the medicines in the first decoction, adding 6 times of water in the 2 nd and 3 rd times, decocting for 0.5h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 100g of dextrin and 5g of colloidal silicon dioxide into each 100g of paste, preparing a soft material, sieving with a 14-mesh sieve, granulating, drying at 60 ℃ until the water content is below 6%, finishing granules, and subpackaging to obtain granules.
Example 11
The formula comprises the following components: 160g of dendrobium candidum, 267g of astragalus membranaceus, 133g of radix pseudostellariae, 133g of radix rehmanniae, 133g of scorched hawthorn fruit and 133g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking for 2 hours, decocting for 3 times, adding 8 times of water of the total weight of the medicines in the first decoction, adding 6 times of water in the 2 nd and 3 rd times, decocting for 0.5 hour, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to clear paste with the relative density of 1.00-1.10 (50 ℃), adding 450g of sucrose, boiling, adding 0.2% of sodium benzoate of the total amount of a prescription, stirring, dissolving, mixing uniformly, filtering, fixing the volume to 1000mL, cooling and packaging to obtain syrup.
Example 12
The formula comprises the following components: 154g of dendrobium candidum, 258g of astragalus membranaceus, 127g of radix pseudostellariae, 127g of radix rehmanniae, 127g of scorched hawthorn fruit and 127g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 6 times of water for the total weight of the medicines in the first decoction, adding 4 times of water for the second and third times, decocting for 0.5h each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 13
The formula comprises the following components: 156g of dendrobium candidum, 261g of astragalus, 129g of radix pseudostellariae, 129g of radix rehmanniae, 129g of scorched hawthorn fruit and 129g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus membranaceus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking in water for 1.5h, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5h each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.15% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 14
The formula comprises the following components: 158g of dendrobium candidum, 264g of astragalus, 131g of radix pseudostellariae, 131g of radix rehmanniae, 131g of scorched hawthorn fruit and 131g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5h each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 15
The formula comprises the following components: 160g of dendrobium candidum, 267g of astragalus membranaceus, 133g of radix pseudostellariae, 133g of radix rehmanniae, 133g of scorched hawthorn fruit and 133g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 3 hours, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5 hour each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 16
The formula comprises the following components: 162g of dendrobium candidum, 270g of astragalus membranaceus, 135g of radix pseudostellariae, 135g of radix rehmanniae, 135g of scorched hawthorn fruit and 135g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 3 hours, decocting for 3 times, adding 10 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 1 hour each time, filtering, combining the filtrates obtained in the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.25% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 17
The formula comprises the following components: 164g of dendrobium candidum, 273g of astragalus membranaceus, 137g of radix pseudostellariae, 137g of radix rehmanniae, 137g of scorched hawthorn fruit and 137g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 3 hours, decocting for 3 times, adding 10 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 1 hour each time, filtering, combining the filtrate obtained by the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.25% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and packaging to obtain the mixture.
Example 18
The formula comprises the following components: 166g of dendrobium candidum, 276g of astragalus mongholicus, 139g of radix pseudostellariae, 139g of radix rehmanniae, 139g of scorched hawthorn fruit and 139g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 4 times of water for the second and third times, decocting for 0.5h each time, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.15% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the mixture.
Example 19
The formula comprises the following components: 168g of dendrobium candidum, 279g of astragalus membranaceus, 130g of radix pseudostellariae, 130g of radix rehmanniae, 130g of scorched hawthorn fruit and 130g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, adding water for 1h, decocting for 3 times, adding water which is 8 times of the total weight of the medicines in the first decoction, adding water which is 6 times of the total weight of the medicines in the second and third times, decocting for 1h, filtering, combining the filtrate obtained by 3 times of decoction, concentrating the filtrate to an extract with the relative density of 1.27-1.34 (50 ℃), adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and subpackaging to obtain the extract.
Example 20
The formula comprises the following components: 168g of dendrobium candidum, 279g of astragalus membranaceus, 127g of radix pseudostellariae, 127g of radix rehmanniae, 127g of scorched hawthorn fruit and 127g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus membranaceus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, adding water for 2.5h, decocting for 3 times, adding water 10 times of the total weight of the medicines in the first decoction, adding water 8 times of the total weight of the medicines in the second and third times, decocting for 1h, filtering, combining the filtrates obtained in the 3 times of decoction, concentrating the filtrate to an extract with the relative density of 1.27-1.34 (50 ℃), adding sodium benzoate accounting for 0.15% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling and packaging to obtain the extract.
Example 21
The formula comprises the following components: 164g of dendrobium candidum, 270g of astragalus membranaceus, 130g of radix pseudostellariae, 130g of radix rehmanniae, 130g of scorched hawthorn fruit and 130g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 6 times of water for the total weight of the medicines in the first decoction, adding 4 times of water for the second and third times, decocting for 0.5h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 100g of dextrin and 5g of colloidal silica into each 100g of paste, preparing a soft material, sieving with a 14-mesh sieve, granulating, drying at 60 ℃ until the water content is below 6%, granulating, and subpackaging to obtain granules.
Example 22
The formula comprises the following components: 160g of dendrobium candidum, 265g of astragalus membranaceus, 135g of radix pseudostellariae, 135g of radix rehmanniae, 135g of scorched hawthorn fruit and 135g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking for 3h, decocting for 3 times, adding 10 times of water of the total weight of the medicines in the first decoction, adding 8 times of water in the second and third times, decocting for 1h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 100g of dextrin and 5g of colloidal silicon dioxide into each 100g of paste, preparing a soft material, sieving with a 14-mesh sieve, granulating, drying at 60 ℃ until the water content is below 6%, finishing granules, and subpackaging to obtain granules.
Example 23
The formula comprises the following components: 165g of dendrobium candidum, 275g of astragalus membranaceus, 129g of radix pseudostellariae, 129g of radix rehmanniae, 129g of scorched hawthorn fruit and 129g of dwarf lilyturf tuber.
The preparation method comprises the following steps: loading six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water of the total weight of the medicines in the first decoction, adding 6 times of water in the 2 nd and 3 rd times, decocting for 0.5h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.20-1.25 (80 ℃), adding 100g of dextrin and 5g of colloidal silica into each 100g of paste, preparing a soft material, sieving with a 14-mesh sieve, granulating, drying at 60 ℃ until the water content is below 6%, grading, and subpackaging to obtain granules.
Example 24
The formula comprises the following components: 165g of dendrobium candidum, 275g of astragalus membranaceus, 129g of radix pseudostellariae, 129g of radix rehmanniae, 129g of scorched hawthorn fruit and 129g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 10 times of water for the total weight of the medicines in the first decoction, adding 8 times of water for the second and third times, decocting for 1h, filtering, combining the filtrates obtained by the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.00-1.10 (50 ℃), adding 430g of sucrose, boiling, adding 0.3% of sodium benzoate in the total amount of the prescription, stirring, dissolving, mixing uniformly, filtering, fixing the volume to 1000mL, cooling and packaging to obtain syrup.
Example 25
The formula comprises the following components: 160g of dendrobium candidum, 265g of astragalus membranaceus, 135g of radix pseudostellariae, 135g of radix rehmanniae, 135g of scorched hawthorn fruit and 135g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 10 times of water for the total weight of the medicines in the first decoction, adding 8 times of water for the second and third times, decocting for 1h, filtering, combining the filtrates obtained by the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.00-1.10 (50 ℃), adding 440g of sucrose, boiling, adding 0.2% of sodium benzoate in the total amount of the prescription, stirring, dissolving, mixing uniformly, filtering, fixing the volume to 1000mL, cooling and packaging to obtain syrup.
Example 26
The formula comprises the following components: 158g of dendrobium candidum, 270g of astragalus, 131g of radix pseudostellariae, 131g of radix rehmanniae, 131g of scorched hawthorn fruit and 130g of dwarf lilyturf tuber.
The preparation method comprises the following steps: putting six medicines of dendrobium candidum, astragalus root, radix pseudostellariae, radix rehmanniae, charred hawthorn and dwarf lilyturf tuber into a filter bag, soaking for 2h, decocting for 3 times, adding 8 times of water of the total weight of the medicines in the first decoction, adding 6 times of water in the 2 nd and 3 rd times, decocting for 0.5h, filtering, combining the filtrates of the 3 times of decoction, concentrating the filtrate to a clear paste with the relative density of 1.00-1.10 (50 ℃), adding 460g of sucrose, boiling, adding 0.2% of sodium benzoate of the total amount of the prescription, stirring, dissolving, mixing uniformly, filtering, fixing the volume to 1000mL, cooling and packaging to obtain syrup.
To further verify the feasibility of the invention, the inventors performed a series of experiments, comprising the following steps:
1. investigation of preparation technique
1. Literature data on the main chemical composition and physicochemical properties of each drug in prescription
1.1 prescription composition
The dendrobium, ginseng and immunity-enhancing mixture prescription consists of six traditional Chinese medicines of dendrobium officinale, astragalus, radix pseudostellariae, scorched hawthorn fruit, dwarf lilyturf tuber and dried rehamnnia root, and the medicinal materials are all a part of the carrier of the 2020 edition of Chinese pharmacopoeia, do not contain toxic medicinal materials, and do not have eighteen antagonisms and nineteen incompatibilities.
1.2 analysis of the Main chemical Components of the herbs in the recipe
Dendrobium officinale: the main active ingredients of the dendrobium polysaccharide, dendrobine, stilbenes and derivatives thereof, trace elements and the like are contained, and the chemical ingredients of the dendrobium candidum are determined at present: polysaccharides, alkaloids, stilbenes, phenols, lignin, and the like, which have a variety of biological activities: regulating immunity, resisting oxidation, resisting tumor, reducing blood sugar, and resisting bacteria. The dendrobium polysaccharide has close relation with the pharmacological activity. The polysaccharide content is the main basis for judging the quality of the dendrobium candidum.
Radix astragali: contains main active ingredients such as saponins, polysaccharides, flavonoids, etc. The saponin compound is one of important active ingredients in astragalus mongholicus, and most of the saponin compounds are tetracyclic triterpenoid saponin compounds. Astragaloside IV (AS-IV) is a main component of astragalus root with heart strengthening effect, and has wide biological activities of protecting heart, resisting inflammation, resisting oxidation, resisting apoptosis, resisting virus, etc. Astragalus Polysaccharides (APS) are the active ingredients with the highest activity in astragalus medicinal materials, and are also the hot content of modern medical research. APS are mainly composed of glucans, including water-soluble and water-insoluble glucans, and heteropolysaccharides, mostly water-soluble acidic heteropolysaccharides. APS participates in regulating organism immunity, and has anti-tumor, anti-infection activity, and cardiovascular protection effects. A great deal of experimental researches show that the APS and the astragaloside have remarkable immunoregulation effect.
Radix pseudostellariae: contains various effective components such as amino acids, polysaccharides, glycosides, phospholipids, cyclic peptides, volatile oil, etc., and the radix Pseudostellariae has various biological activities such as enhancing organism, promoting immunity, SOD-like effect, relieving cough, resisting bacteria, and resisting virus.
Radix rehmanniae: the main chemical components are saccharides, iridoid glycoside, amino acid and the like, which are also main active components. 8 sugars have been isolated and identified from rehmannia: stachyose, raffinose, glucose, sucrose, fructose, mannyltriase, verbascose and galactose. The rehmannia root has the highest polysaccharide component content and better water solubility, wherein the content of reducing sugar is 140.3-287.3mg.g < -1 >; the polysaccharide content is 31.3-50.5 mg g < -1 >. Rehmannia has the pharmacological activities of resisting oxidation, resisting aging, exciting immunity, reducing blood sugar, resisting cancer, resisting cerebral ischemia, protecting nerve center, promoting hematopoiesis and the like. The rehmannia polysaccharide has many pharmacological effects of resisting tumor, enhancing immunity, promoting hematopoiesis, reducing blood sugar, resisting oxidation, resisting anxiety, inducing BMSCs to differentiate into neuron-like cells, and is one of the main active ingredients of rehmannia. The pharmacological experiment of the rehmannia glycoside D, A shows that the rehmannia glycoside D, A has the effects of nourishing yin, enriching blood and reducing blood sugar, and the research shows that the rehmannia glycoside D, A has good water solubility and strong thermal stability.
Radix Ophiopogonis: steroid saponins, homoisoflavonoids and ophiopogonpolysaccharide are the main active ingredients of ophiopogon root. The ophiopogon root flavone has wide and effective functions of resisting myocardial ischemia, resisting thrombosis, resisting oxidation, enhancing immunity, resisting aging and other physiological functions, and the monosaccharide composition of the ophiopogon root polysaccharide compound mainly comprises fructose and glucose. The ophiopogon polysaccharide has the effects of reducing blood sugar, regulating immunity, relieving asthma, resisting allergy, resisting anoxia, resisting tumor, resisting myocardial ischemia and treating gastrointestinal tract.
And (3) burnt hawthorn: hawthorn is a medicinal and edible plant and contains various chemical components such as flavonoid, flavane, polymers thereof, triterpenes, organic acids and the like. The fructus crataegi total flavone has blood pressure lowering effect. Flavone in fructus crataegi is the main component for reducing blood lipid. The fructus crataegi decoction has effect in promoting cellular immunity of mice. Hawthorn flavone is a recognized class of compounds with the highest antioxidant potential.
2. Dosage form selection
The Hushen immunopotentiator is derived from an empirical formula derived from the teaching of the national academic inheritance Chen Zhu of the traditional Chinese medicine specialist. Dendrobium officinale and ginseng mixture has the effects of nourishing yin, clearing heat, tonifying qi, promoting fluid production and tonifying stomach. The decoction is used as a medicine clinically, and has better curative effect. In order to facilitate the administration of patients, the subject group systematically researches the preparation process of the dendrobium ginseng immunity enhancing mixture by combining the clinical traditional usage and the physicochemical properties of chemical components in prescription decoction pieces according to the related requirements of the medical institution for implementing record management of Chinese medicinal preparation by applying the traditional process issued by the drug administration of Guizhou province, and performs pilot-scale production, simultaneously performs qualitative and quantitative researches and control on main effective components, establishes quality standards, and provides data support for the subsequent production of products with stable and controllable quality and curative effect. Referring to the clinical practice, the final formulation is selected as a mixture.
3. Prescription Process study
According to the physicochemical properties of the medicines in the formula, most of the effective components are water-soluble components, the water extraction mode is proper for retaining most of the effective components, and meanwhile, the water extraction technology is adopted in the whole formula combined with the requirements of the traditional preparation record, so that microorganisms are easy to breed in the storage process of the liquid preparation, and therefore, the bacteria inhibitor is also required to be screened to ensure the stability of the product. Through researches, the process route of the product is determined as follows: decocting six decoction pieces of Dendrobium officinale and Astragalus membranaceus in water, concentrating the water extract to obtain a liquid medicine, adding sodium benzoate in a prescription amount, stirring and dissolving to obtain a bacteriostatic agent, filtering, filling and obtaining a finished product.
Next, we elaborate the process of the prescription of the dendrobium nobile ginseng immune enhancing mixture from the extraction process, the concentration process and the screening of bacteriostat.
3.1 research on extraction Process
The extraction process of the traditional Chinese medicine decoction pieces is a key ring in the preparation process of the traditional Chinese medicine preparation, and the water absorption rate, the soaking process and the decocting process parameters of the decoction pieces are required to be examined in detail so as to screen out the proper extraction process. Through research, we finally determine that decoction pieces are soaked in 8 times of water for 2 hours, decocted for 30 minutes, added with 6 times of water for the second time and the third time, decocted for 30 minutes, combined with the three times of extracting solution, and screened by a 100-mesh sieve for standby.
3.1.1 determination of Water absorption of decoction pieces
Weighing 36g of decoction pieces with 1/2 clinical prescription, soaking in 10 times of water for different times, filtering, weighing wet medicine (until decoction pieces weight is not increased), and measuring water absorption of decoction pieces with the following formula (the result is shown in Table 1).
mb-quality of decoction pieces in saturated state of water absorption (g)
mg-quality of decoction pieces in dry state (g)
Table 1 investigation of water absorption of decoction pieces
As can be seen from Table 1, the water absorption of the decoction pieces after soaking for 24 hours was about 1.7 times, and the water absorption was calculated as 2 times for convenience of operation, i.e., the water absorption of the decoction pieces was 2 times the weight of the decoction pieces. Therefore, the water which is 2 times of the weight of the decoction pieces should be added for the first extraction.
3.1.2 determination of soaking time
Under the condition of meeting the water absorption of decoction pieces, the influence of soaking time on the prescription paste yield and the extraction of active ingredients is examined, and the total solid yield and the astragaloside IV content in the extracting solution are taken as examination indexes, so that the proper soaking time is optimized.
3.1.2.1 preparation of the extract
Weighing 36g of decoction pieces with the clinical prescription dosage of 1/2, adding 12 times of water for the first time and 10 times of water for the second time, considering that bacteria are easy to breed and deteriorate due to overlong soaking time of water decoction, and combining the feasibility of mass production, we design to soak 0.5 hour, 1 hour, 2 hours, 4 hours, 6 hours and not soak several samples, decoct for 2 times for 30 minutes each time, filter, combine the filtrates, and fix the solution to 250mL for later use.
3.1.2.2 Total solids yield determination
25mL of the liquid medicine prepared in the step 3.1.2.1 is precisely removed, two parts of the liquid medicine are added into an evaporation dish with constant weight, the liquid medicine is evaporated to dryness in a water bath, the liquid medicine is dried at 105 ℃, the total solid matter weight is measured according to a method of the general constant weight of the part of the 2020 edition of Chinese pharmacopoeia, and the total solid matter yield is calculated, and the formula is as follows (the result is shown in Table 2, and the analysis of variance is shown in Table 3).
W is the weight of solids in 25mL of filtrate, V is the constant volume, and Wt is the sample feeding weight.
TABLE 2 influence of soaking time on paste yield
TABLE 3 one-factor analysis of variance table of soaking time versus paste yield
The small knot: analysis of variance of one factor shows that: p is less than 0.05, which indicates that different soaking times have significant differences;
the soaking time has a certain influence on the paste yield. Although the paste yield of the sample prepared by soaking for 6 hours and then decocting is slightly high, the selection of 2 hours is suitable from the viewpoints of time cost and possibility of microorganism growth due to too long soaking time.
3.1.2.3 Astragaloside IV content determination
(1) Preparation of control solution
Taking 5mg of astragaloside IV reference substance, precisely weighing, placing into a 10mL volumetric flask, dissolving with methanol to constant volume, filtering with 0.45um filter membrane, and collecting the subsequent filtrate to obtain reference substance solution.
(2) Preparation of test solutions
And (3) precisely removing 20mL of the liquid medicine prepared in the step 2.1.1, extracting with 50mL, 25mL and 25mL water saturated n-butanol respectively, mixing the four extracts, adding ammonia test solution (400 mL of ammonia water is diluted to 1000 mL) for 3 times, removing 20mL of the washing solution each time, adding the n-butanol layer into an evaporating dish, volatilizing in water bath, dissolving residues with methanol to 5mL, filtering with a 0.45um filter membrane, and obtaining a subsequent filtrate to obtain a sample solution.
(3) Sample measurement
Adopting high performance liquid chromatography and an evaporative light detector to measure the astragaloside IV content, wherein the liquid phase condition is as follows: chromatographic column: irite BDS-C18 (4.6 mm×250mm,5 um), mobile phase: acetonitrile-water (38:62), volumetric flow: 1mL.min-1, column temperature: 40 ℃. Sample injection volume: the reference solutions are 20uL and 5uL respectively, the sample solution is 20uL, the content is calculated by adopting an external standard two-point logarithmic equation, and the results are shown in tables 4 and 5.
Table 4 investigation of astragaloside IV content by soaking time
TABLE 5T test results for single sample
The small knot: from the single sample T test results, it can be seen that: p is less than 0.05, which shows that different soaking time has a certain influence on the content of astragaloside, and the content of astragaloside in a sample prepared by soaking for 2 hours and then decocting is slightly higher.
Conclusion: by combining the results of the ointment yield and the astragaloside IV and combining the actual situation of mass production, we choose to soak for 2 hours and then decoct.
3.1.3 screening of decoction Process
The whole prescription adopts a water extraction process, 6 Chinese medicinal decoction pieces such as dendrobium officinale and the like in the prescription are filled into a double-layer filter bag, soaked for 2 hours by adding water, tested according to an orthogonal test design table, the decoctions are combined, three main factors influencing the decocting effect are filtered, the decocting times, the decocting time and the water adding amount are inspected, and according to the level of 3 of each factor, L is used 9 (3 4 ) Orthogonal table arrangement test (table 6). The process is evaluated by taking the ointment yield and the astragaloside IV content as indexes, the water extraction condition is optimized, and the results are shown in tables 7-10.
3.1.3.1 determination of the paste yield: concentrating to 150mL according to the volume of the decoction, precisely taking 20mL to an evaporation dish with constant weight, evaporating in water bath, drying at 105 ℃ to constant weight, and weighing to calculate the paste rate with the following formula.
W is the weight of solids in the extracted liquid, and Wt is the weight of the sample.
3.1.3.2 determination of Astragaloside IV transfer Rate:
(1) Preparation of control solution
Taking 5mg of astragaloside IV reference substance, precisely weighing, placing into a 10mL volumetric flask, dissolving with methanol to constant volume, filtering with 0.45um filter membrane, and collecting the subsequent filtrate to obtain reference substance solution.
(2) Preparation of test solutions
And (3) precisely removing 20mL of the liquid medicine prepared in the step 2.1.1, extracting with 50mL, 25mL and 25mL water saturated n-butanol respectively, mixing the four extracts, adding ammonia test solution (400 mL of ammonia water is diluted to 1000 mL) for 3 times, removing 20mL of the washing solution each time, adding the n-butanol layer into an evaporating dish, volatilizing in water bath, dissolving residues with methanol to 5mL, filtering with a 0.45um filter membrane, and obtaining a subsequent filtrate to obtain a sample solution.
(3) Sample treatment for determining astragaloside IV content in astragalus decoction pieces
Taking about lg of the product powder (sieving with a fourth sieve), precisely weighing, placing into a conical flask with a plug, precisely adding 50ml of 80% methanol solution containing 4% of concentrated ammonia test solution (taking 4ml of concentrated ammonia test solution, adding 80% of methanol to 100ml, shaking uniformly), weighing by a seal plug, heating and refluxing for 1 hour, cooling, weighing by a certain weight, supplementing the lost weight with 80% methanol solution containing 4% of concentrated ammonia test solution, shaking uniformly, filtering, precisely measuring 25ml of continuous filtrate, evaporating to dryness, dissolving the residue with 80% methanol, transferring to a 5ml measuring flask, adding 80% of methanol to scale, shaking uniformly, filtering, and taking the continuous filtrate to obtain the product.
(4) Sample measurement
Adopting high performance liquid chromatography and an evaporative light detector to measure the astragaloside IV content, wherein the liquid phase condition is as follows: chromatographic column: irite BDS-C18 (4.6 mm×250mm,5 um), mobile phase: acetonitrile-water (38:62), volumetric flow: 1mL.min -1 Column temperature: 40 ℃. Evaporative light scattering detector conditions: drift tube temperature (80 ℃), atomizing temperature (40 ℃) nitrogen flow rate (1.6 SLM). Sample injection volume: the reference substance solutions are 20uL and 5uL respectively, the sample solution is 20uL, and the content is calculated by adopting an external standard two-point logarithmic equation.
(5) Astragaloside IV transfer rate calculation
C1 is astragaloside IV content (mg.mL) in the extractive solution -1 ) C2 is the astragaloside IV content (%), g/g) in the astragalus decoction pieces, and Wt is the feeding weight (g) of the astragalus decoction pieces.
TABLE 6 factor level Table
TABLE 7 analysis of variance of% of paste yield in decoction process conditions L9 (34) orthogonal test
TABLE 8 decoction process conditions L9 (34) orthogonal test Astragaloside IV transfer% variance analysis table
TABLE 9 decoction process conditions L9 (34) orthogonal test comprehensive analysis of variance table
Visual analysis of Table 10
Analysis of results: from visual analysis, the influence of each factor on the ointment yield and the astragaloside IV comprehensive component is A>C>B, the best scheme is A 1 B 3 C 3 The method comprises the steps of carrying out a first treatment on the surface of the However, the analysis of variance results show that the factor A has significant difference, and the follow-up concentration time is overlong due to excessive water addition, so that the decoction is selected to be 3 times, 30 minutes each time, and the water addition multiple is 6 times as the optimal extraction process, A 3 B 1 C 1 . Combining the research results of the water absorption and the soaking time, the final extraction process is that 8 times of water is added for soaking for 2 hours, the water is added for 30 minutes for 2 times and 3 times, the water is added for 6 times, the water is decocted for 30 minutes, the three extraction solutions are combined, and the three extraction solutions are screened by a 100-mesh sieve for standby.
3.1.3.3 three-batch sample extraction process verification experiment
Taking clinical prescription decoction pieces according to the optimal extraction process condition A 3 B 1 C 1 Extraction, determination of paste rate and astragaloside IV transfer rate, and the results show (see Table 11): the average value of the paste yield is 34.9%, and the RSD% is 0.2%; astragaloside IV transfer rate 45.3%, rsd=1.4%, comprehensive score 99, rsd=1.2%, consistent with expectations, demonstrating that the extraction process is stable and feasible.
Table 11 extraction process validation test
The small knot: according to the research results, the water extraction process is preliminarily determined, the water absorption and soaking time research results are combined, the finally determined extraction process is that 8 times of water is added for 2 hours, the water is decocted for 30 minutes, 6 times of water is added for the second time and the third time, the water is decocted for 30 minutes, and the three times of extraction solutions are combined for standby.
3.2 research on concentration Process
Because the preparation is a mixture of the traditional process, the traditional habit and the actual production condition are considered, and normal pressure concentration is adopted.
Weighing 1 clinical prescription decoction pieces, extracting according to the optimal process of 3.1, concentrating the decoction at normal pressure to about 150mL, 120mL, 100mL and 75mL, observing the properties of the solution, and determining the content and relative density of astragaloside IV (20 ℃ C., according to the relative density check method of 0601 of the edition 2020 of Chinese pharmacopoeia), and the results are shown in tables 12 and 13.
TABLE 12 Properties and relative Density (20 ℃ C.) of the extracts at different levels of concentration
TABLE 13 extraction yield of Astragaloside IV for different levels of concentration of the extracts
The small knot: as can be seen from the results of the samples with different concentrated volumes of 3 batches of samples, 1 clinical prescription dose decoction piece is concentrated to 150mL, 120mL, 100mL and 75mL according to the formulated process, the amounts of astragaloside IV in each sample are not significantly different, the relative density is increased along with the reduction of the final volume of concentration, and the concentration is sticky when the final volume of 75mL is reached, the concentration is easy to cause gelatinization and difficult to control, so that the concentration to a greater degree is not carried out any more. To determine the concentration endpoint, we again examined, taking 150mL of the extract, concentrating to about 75mL, and taking the relative density at 50 ℃ as the concentration endpoint judgment basis. And meanwhile, the concentrated solution is cooled to room temperature to measure the pH value, so that a basis is provided for the selection of the subsequent bacteriostat. The results of the investigation are shown in Table 14:
TABLE 14 concentrated liquid phase Density (50 ℃) and pH determination
The small knot: according to the research results, 1 clinical prescription decoction piece is initially decocted according to a determined decoction process, and then the decoction liquid is combined, filtered and the extract liquid is concentrated to about the relative density of 1.1 (50 ℃) for standby.
3.3 selection of bacteriostat
Because the product is prepared by a water extraction process, the product is easy to deteriorate and mould in the storage process. In order to increase the stability of the mixture and ensure the quality of the preparation, an effective bacteriostatic agent must be selected. According to the first edition of Chinese pharmacopoeia 2020, the most commonly used bacteriostats for medicine are benzoic acid and its sodium salt, sorbic acid and its potassium salt, and hydroxyphenyl ethyl esters, respectively. Benzoic acid and sodium salt thereof are acid preservative, and have stronger antibacterial effect when the pH is 2.5-4; when the pH is more than 5.5, the antibacterial effect is obviously weakened. Sorbic acid and potassium salts thereof are also acidic preservatives, have a good inhibitory effect on fungi and yeasts and are suitable for a pH range of <6. Although the ethylparaben has wide antibacterial effect on mould, yeast and bacteria, the ethylparaben is poor in water solubility and almost insoluble in water, and the clarity of the ethylparaben is affected by adding the ethylparaben to a mixture. Meanwhile, most of bacteriostats selected by referring to a plurality of mixture products in pharmacopoeia are potassium sorbate and sodium benzoate. Therefore, we initially select potassium sorbate and sodium benzoate for investigation, and according to the bacteriostasis efficacy inspection method of 1121 in the Chinese pharmacopoeia 2020 edition, examine each prescription amount of bacteriostat to screen out the best bacteriostat suitable for the product, we determine the pH value of the solution obtained by each bacteriostat prescription, and the results of each concentration of bacteriostat are shown in Table 15; meanwhile, we count the reduced lg values of 14 days and 28 days relative to the previous time point, and according to the antibacterial effectiveness test result, the two antibacterial agents can meet the requirements within the concentration range of 0.20-0.30%. However, the bacteriostatic efficacy of sodium benzoate is stronger, and in order to ensure the stability of the storage process and also consider the principle of minimum bacteriostatic concentration, 0.2% of sodium benzoate is selected as the bacteriostatic agent of the product, and the detailed study data are shown in Table 16.
TABLE 15 effect of bacteriostat on pH of solution results
Table 16 reduced lg values for 14 and 28 days of incubation of samples from each of the bacteriostat formulas
Remarks: the difference value of the reduced lg value is the difference value between the lg value of the bacterial count measured at each interval and the lg value at the previous time point.
According to the research results, the water extraction process is preliminarily determined, and the water absorption and soaking time research results are combined, wherein the finally determined extraction process is that 8 times of water is added for soaking for 2 hours, the water is decocted for 30 minutes, the second time and the third time are added with 6 times of water, the water is decocted for 30 minutes, the three times of extraction solutions are combined, filtered and concentrated to have the relative density of about 1.1 (50 ℃), and 0.2% of sodium benzoate is added for stirring and dissolving, so that the water-soluble compound medicine is obtained.
3.4 confirmation of the preparation Process by small trial
According to the research results, the whole prescription is preliminarily determined by adopting a water extraction process and combining the research results of water absorption and soaking time, the finally determined extraction process is that 8 times of water is added for 2 hours, the water is decocted for 30 minutes, 6 times of water is added for the second time and the third time, the water is decocted for 30 minutes, the three times of extraction solutions are combined, the concentration is carried out to 150mL, the relative density (50 ℃) is measured, and the prescription sodium benzoate is added for stirring and dissolution, thus obtaining the water-soluble sodium benzoate. The preparation process is used for preparing 3 batches of small test samples, the relative density (20 ℃) of finished products, the pH value, the astragaloside IV content of the finished products and the related examination of appearance properties, and the results are shown in tables 17 to 21.
Table 17 Small test confirmation batch intermediate relative Density test results (50 ℃ C.)
Table 18 Small test confirmation batch of the results of the relative Density test (20 ℃ C.)
The small knot: the results show that the relative densities of the three batches of samples are between 1.14 and 1.15, and the relative densities of the three batches of samples are relatively close.
Table 19 results of the pilot-test confirmation batch pH test
The small knot: the results show that the pH values of the three batches of samples are between 4.51 and 4.62, and the pH values of the three batches of samples are relatively close.
Table 20 test results of the test for confirming the properties of the batch
Table 21 test results of determination of Astragaloside IV content of the finished product
3.5 pilot study
Based on the above results, combined with the production facility of this hospital, we initially developed a pilot production prescription process. The mass production is amplified by 10 times according to the planned preparation process conditions. The quality of the finished product is evaluated by comprehensively examining the production process indexes. The relative density (20deg.C), pH, astragaloside IV content and loading of the final product were examined and the results are shown in tables 22-28.
Table 22 intermediate relative Density measurement (50 ℃ C.)
Table 23 shows the results of the relative density measurement of the sample products (20 ℃ C.)
The small knot: the results show that the relative densities of the three batches of samples are between 1.12 and 1.14, and the relative densities of the three batches of samples are relatively close. The relative density of the product is controlled between 1.12 and 1.14 by preliminary determination.
Table 24, sample finished product pH detection results (20 ℃ C.)
The small knot: the results showed that the pH values of the three batches were between 4.62 and 4.58.
Table 25 shows the results of the test sample finished product loading test (n=3)
The small knot: taking 3 bottles of the product according to four general rules 0942 (minimum filling quantity inspection method) of the Chinese pharmacopoeia 2020 edition, and measuring the filling quantity (standard: average filling quantity is not less than labeled quantity, and each container filling quantity is not less than 97% of labeled filling quantity), wherein the result shows that the filling quantity of three batches of samples is greater than 150mL, and the three batches of samples meet the regulations.
Table 26 results of finished product property test
Table 27 determination of Astragaloside IV
Table 28 statistical Table of pilot plant results
The pilot-scale production results show that various indexes of pilot-scale samples prepared by adopting the set parameters meet the requirements, and the process conditions are stable and controllable, thus the process is feasible.
2. Experimental effects and summary
The pilot-scale production results show that various indexes of pilot-scale samples prepared by adopting the set parameters meet the requirements, and the process conditions are stable and controllable, so that the optimized process can be used for mass production of the product.
After the decoction is developed into the mixture, the medicinal effect substances of the traditional decoction are maintained, the stability of the product is improved, the dosage is reduced, and the decoction is more convenient for patients to carry.
The successful development of the project can bring good news to a plurality of patients, improve the life quality of the patients and lighten the economic burden, and has positive significance for families of the patients and even the whole society. The variety of the hospital preparation is expanded and enriched, and the people are benefited. Meanwhile, the multi-scale development of the large health industry in our province is promoted, so that the dendrobium industry becomes a new development bright point of the large health industry in Guizhou.
Reference is made to:
[1] chen Xiaomei, wang Chunlan, yang Junshan, etc. Dendrobium officinale chemical components and analytical research progress [ J ] J.Chinese pharmaceutical J2013,48 (19): 1634-1640.
[2] Zhang Banglei, yang Haonan, shen Xiaojing, etc. Dendrobium officinale chemical components and their pharmacological efficacy research progress [ J ]. J.J.J.Chem.Chem.F. 2019,6 (54): 3,8.
[3] Zhang Zhouying, yang Chengmi, blue loyal, etc. dendrobe polysaccharide antibacterial action study [ J ]. Chinese medical guidelines, 2012, (33) 439.
[4] Hou Shaozhen, li Huanbin, guo Jianru, et al Dendrobium officinale analgesic and anti-inflammatory action study [ J ]. Animal medicine progress, 2012,33 (10): 49-52.
[5] Nie Juan, xie Lihua, marong round, etc. the research on the chemical composition and pharmacological action of radix astragali [ J ]. Hunan J.Chinese medicine, 2018,34 (7): 228-231.
[6]Huang YF,Lu L,Zhu DJ,et al.Effects of Astragalus Polysaccharides on Dysfunction of Mitochondrial Dynamics Induced by Oxidative Stress[J].Oxidative Medicine and Cellular Longevity,2016,6(1):1-13.
[7] Li Qin, hu Jihong, gaobao, et al recent research in immunomodulation by APS [ J ]. J.J.Chinese experimental prescription, 2017 (2): 199-206.
[8]Nan L I,Ying F,XuMing J,et al.Effect of Astragali Radix Active Ingredients on Serum Insulin and Adiponectin in Diabetes Rats[J].Chinese Journal of Experimental Traditional FormulaeMedical,2011,17(5):144-146.
[9] Xu Xueqin, long Quanjiang, zhao Jian. Research on chemical composition, pharmacological action and processing technique of radix Pseudostellariae [ J ]. Modern Chinese medicine research and practice 2014,28 (4): 73-75.
[10] Li Chuanhou and Wang Rui the chemical composition of radix Pseudostellariae is developed [ J ]. Shandong medical science, university school journal, 2017,39 (3): 229-231.
[11] Guo Lin, miao Ming, chemical, pharmacological and application characteristics of fresh rehmannia root [ J ]. Chinese medicine report, 2014,29 (3): 375-377.
[12] Wang Zhijiang, wei Guodong, ma Sai, research progress on chemical and pharmacological actions of rehmannia polysaccharide [ J ]. J.Chinese experimental prescription journal, 2015,21 (16): 231-234, seal 3.
[13] Wang Huisen, li Gengsheng, liu Ming, etc. separation and identification of iridoid glycoside in fresh rehmannia root [ J ]. Chinese medicine research, 2005,18 (4): 17-19.
[14] Kuangxiang nana, zhu Na, liu Shiqiao, radix Ophiopogonis chemical composition research [ J ]. Chinese pharmaceutical industry, 2018,27 (2): 19-22.
[15] Luo Xiao, zhang Xingguo, yang Yanchen, etc. the research progress of flavonoid components of ophiopogon root [ J ]. Chinese traditional medicine science and technology, 2015,22 (5): 603-605.
[16] Zeng Fanyu, li Saiyao, dan. Pharmacology research of ophiopogon polysaccharide is progressed [ J ]. Strait pharmaceutical, 2018,30 (1): 55-57.
[17] Jiang Jianfang, shen Xiaolan, zhang Ning effects of fructus crataegi total flavonoids on rat vascular function in vitro and its mechanism [ J ]. Pharmaceutical applications in modern China 2011, 28 (7): 614-617.
[18] Xie Weihua, sun Chao, liu Shumin. Influence of hawkthorn flavone on transcriptional expression of lipid-producing genes in mice with hyperlipidemic model [ J ]. Journal of chinese traditional chinese medicine, 2009, 02:224-229.
[19] Niu Xixiang, chen Mimi, huai Hua, development of chemical composition and pharmacological action of fructus crataegi [ J ] dietary care, 2018,5 (42): 58-59.
Claims (10)
1. The dendrobium candidum and ginseng immunity enhancing pharmaceutical composition is characterized by comprising the following medicines in parts by weight: 152-168 parts of dendrobium candidum, 255-279 parts of astragalus membranaceus, 125-141 parts of radix pseudostellariae, 125-141 parts of radix rehmanniae, 125-141 parts of scorched hawthorn fruit and 125-141 parts of dwarf lilyturf tuber.
2. The pharmaceutical composition of dendrobium nobile lindl ginseng immunity enhancing as claimed in claim 1, wherein the composition is composed of the following medicines in parts by weight: 154-166 parts of dendrobium candidum, 258-276 parts of astragalus membranaceus, 127-139 parts of radix pseudostellariae, 127-139 parts of radix rehmanniae, 127-139 parts of scorched hawthorn fruit and 127-139 parts of dwarf lilyturf tuber.
3. The pharmaceutical composition of dendrobium nobile lindl ginseng immunity enhancing as claimed in claim 1, wherein the composition is composed of the following medicines in parts by weight: 156-164 parts of dendrobium candidum, 261-273 parts of astragalus membranaceus, 129-137 parts of radix pseudostellariae, 129-137 parts of radix rehmanniae, 129-137 parts of scorched hawthorn fruit and 129-137 parts of dwarf lilyturf tuber.
4. The pharmaceutical composition of dendrobium nobile lindl ginseng immunity enhancing according to claim 1, wherein the composition is composed of the following medicines in parts by weight: 158-162 parts of dendrobium candidum, 264-270 parts of astragalus membranaceus, 131-135 parts of radix pseudostellariae, 131-135 parts of radix rehmanniae, 131-135 parts of scorched hawthorn fruit and 131-135 parts of dwarf lilyturf tuber.
5. The pharmaceutical composition of dendrobium nobile lindl ginseng immunity enhancing according to claim 1, wherein the composition is composed of the following medicines in parts by weight: 160 parts of dendrobium candidum, 267 parts of astragalus membranaceus, 133 parts of radix pseudostellariae, 133 parts of radix rehmanniae, 133 parts of scorched hawthorn fruit and 133 parts of dwarf lilyturf tuber.
6. A process for preparing a pharmaceutical composition according to any one of claims 1 to 5, comprising the steps of: loading six medicines of dendrobium officinale, astragalus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber in a prescription amount into a filter bag, soaking in water for 0.5-6h, decocting for 3 times, adding water which is 6-10 times of the total weight of the medicines in the first decoction, adding water which is 4-8 times of the total weight of the medicines in the second and third times, decocting for 0.5-1.0h each time, filtering, merging the decoctions, concentrating the filtrate to an extract with relative density of 1.05-1.18 at 50 ℃, adding sodium benzoate with the total amount of 0.1-0.3%, stirring, dissolving, mixing, cooling, and split charging the collected filtrate into pharmaceutically acceptable auxiliary materials to prepare a pharmaceutically acceptable dosage form.
7. The method of preparing a pharmaceutical composition according to claim 6, comprising the steps of: filling six medicines of dendrobium officinale, astragalus, radix pseudostellariae, radix rehmanniae, scorched hawthorn fruit and dwarf lilyturf tuber into a filter bag, soaking in water for 2 hours, decocting for 3 times, adding 8 times of water for the total weight of the medicines in the first decoction, adding 6 times of water for the second and third times, decocting for 0.5 hour each time, filtering, combining the filtrates of 3 times of decoction, concentrating the filtrate to an extract with relative density of 1.10-1.13 at 50 ℃, adding sodium benzoate accounting for 0.2% of the total amount of the prescription, stirring, dissolving, mixing uniformly, cooling, subpackaging, and preparing the obtained filtrate or adding pharmaceutically acceptable auxiliary materials into the collected filtrate to prepare a pharmaceutically acceptable dosage form.
8. The method of preparing a pharmaceutical composition according to any one of claims 6 or 7, wherein the acceptable excipients are one or more of sodium benzoate, potassium sorbate, sucrose, maltose, crystal sugar, refined honey, dextrin, colloidal silica, starch.
9. The method of preparing a pharmaceutical composition according to any one of claims 6 or 7, wherein the acceptable dosage form is a mixture, a paste, a granule, a syrup, a pill, a tablet.
10. The dendrobium nobile lindl ginseng immunity-enhancing pharmaceutical composition is characterized by being applied to the preparation of medicines for treating or/and preventing children's lung-spleen yin deficiency.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211370461.9A CN116077586A (en) | 2022-11-03 | 2022-11-03 | Dendrobium officinale and ginseng immunity enhancing pharmaceutical composition and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211370461.9A CN116077586A (en) | 2022-11-03 | 2022-11-03 | Dendrobium officinale and ginseng immunity enhancing pharmaceutical composition and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116077586A true CN116077586A (en) | 2023-05-09 |
Family
ID=86207025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211370461.9A Pending CN116077586A (en) | 2022-11-03 | 2022-11-03 | Dendrobium officinale and ginseng immunity enhancing pharmaceutical composition and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116077586A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146256A (en) * | 2014-08-19 | 2014-11-19 | 遵义医学院 | Dendrobium stem health-care oral liquid capable of nourishing stomach and preparation method thereof |
CN114259543A (en) * | 2021-11-05 | 2022-04-01 | 太和康美(北京)中医研究院有限公司 | Dendrobium nobile composition and preparation method and application thereof |
-
2022
- 2022-11-03 CN CN202211370461.9A patent/CN116077586A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146256A (en) * | 2014-08-19 | 2014-11-19 | 遵义医学院 | Dendrobium stem health-care oral liquid capable of nourishing stomach and preparation method thereof |
CN114259543A (en) * | 2021-11-05 | 2022-04-01 | 太和康美(北京)中医研究院有限公司 | Dendrobium nobile composition and preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
佚名: "太子参黄芪党参石斛功效与作用", pages 1, Retrieved from the Internet <URL:https://www.jyfs.org/effect_73166> * |
蔡光先;李娟;李顺祥;黄丹;赵兴兵;: "铁皮石斛古代与现代的应用概况", 湖南中医药大学学报, no. 05, pages 77 - 81 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100374538C (en) | Fire internal organ nourishing wine and its preparation technology | |
CN104771563B (en) | The compound Chinese medicinal preparation and preparation method of a kind of kidney tonifying | |
CN104856968B (en) | A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof | |
CN103394045B (en) | Chinese medicine composition and preparation method and application thereof | |
CN102120015A (en) | Traditional Chinese medicine for soothing liver and dispersing depressed vital energy and soothing nerves and sedating mind, and preparation method and quality standard thereof | |
Li | Chinese herbal medicine | |
CN102068507A (en) | Preparation method of Chinese medicinal capsules for tonifying lung and activating blood circulation | |
CN103463425B (en) | A kind of treat blood-stasis internal-depression Chinese medicine extract and preparation and method for making | |
CN113116801A (en) | Composition for improving skin sub-health state and preparation method thereof | |
CN105255670A (en) | Health white wine for preventing and treating hypertension, hyperlipidemia and hyperglycemia and preparation method of health white wine | |
CN104771595B (en) | A kind of Chinese medicine composition of strengthen immunity and preparation method thereof | |
CN116077586A (en) | Dendrobium officinale and ginseng immunity enhancing pharmaceutical composition and preparation method and application thereof | |
CN101011543B (en) | Antineoplastic medicine composition | |
CN103316074A (en) | Medicine composite of halenia corni extract, astragalus extract and liquorice extract as well as preparation and application of medicine composite | |
CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
CN112655964A (en) | Concentrated nutrient solution and preparation method thereof | |
CN102233089B (en) | Traditional Chinese medicine composition and preparation method thereof | |
CN105125898A (en) | Medicinal preparation containing milkvetch roots and gastrodia elata and having function of tonifying qi and nourishing blood | |
CN111419946A (en) | Medicine for treating infertility and preparation method thereof | |
CN104547803A (en) | Traditional Chinese medicine composition for postpartum fevers of women for clearing away heat and toxic materials | |
CN108014226A (en) | A kind of Chinese medicine for being used to lose weight | |
CN107970297A (en) | A kind of medicine of tranquilizing and allaying excitement | |
CN113952435B (en) | Traditional Chinese medicine composition for adjuvant treatment of liver cancer and preparation method thereof | |
CN1994426B (en) | Preparation method, and identification and assaying method of 'Sheng Mai' soft capsule | |
CN105796871A (en) | Traditional Chinese medicine composition for enriching yin and nourishing kidneys and preparation method of traditional Chinese medicine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |